{
    "clinical_study": {
        "@rank": "104379", 
        "arm_group": [
            {
                "arm_group_label": "R-miniCHOP", 
                "arm_group_type": "Active Comparator", 
                "description": "All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m\u00b2 D1 - DOXORUBICINE IV : 25 mg/m\u00b2 D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m\u00b2 D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1\n*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
            }, 
            {
                "arm_group_label": "R2-miniCHOP", 
                "arm_group_type": "Experimental", 
                "description": "All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m\u00b2 D1 - DOXORUBICINE IV : 25 mg/m\u00b2 D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m\u00b2 D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14\n*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of R2-miniCHOP (Sub-cutaneous\n      Rituximab-miniCHOP + lenalidomide) and R-miniCHOP (Sub-cutaneous Rituximab-miniCHOP) in\n      patients aged 80 years old or more with not previously treated CD20+ diffuse large B-cell\n      lymphoma as measured by the overall survival (OS).The SENIOR trial will evaluate the\n      tolerance and efficacy of the combination of the R2-miniCHOP regimen and compare this\n      experimental arm to the standard R-miniCHOP regimen.The statistical plan is based on the\n      hypothesis of an increase by 15% of the 2y-OS in favor of the experimental arm, as compared\n      to the reference arm (R-miniCHOP)."
        }, 
        "brief_title": "Efficacy of Lenalidomide in Combination With SC Rituximab + miniCHOP in DLBCL Patients of 80 Years Old or More", 
        "condition": "Diffuse Large B Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO\n             classification 2008) including all clinical subtypes (primary mediastinal,\n             intravascular, etc\u2026), with all aaIPI.\n\n        May also be included: De Novo transformed DLBCL from low grade lymphoma (Follicular,\n        other...) and DLBCL associated with some small cell Infiltration in bone marrow or lymph\n        node; or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or\n        with intermediate features between DLBCL and classical Hodgkin lymphoma; or CD20+\n        Follicular lymphoma grade 3B; or CD20+ Aggressive B-cell lymphoma unclassifiable.\n\n          -  With a CD10 immunostaining performed by the participating center pathologist\n\n          -  Aged \u2265 80 years old\n\n          -  Ann Arbor stage II, III or IV\n\n          -  Patient previously untreated for DLBCL Lymphoma\n\n          -  ECOG performance status \u2264 2\n\n          -  With a minimum life expectancy of 3 months\n\n          -  Negative HIV, HBV (anti-HBc negativity) and HCV serologies test within 4 weeks before\n             inclusion (except after vaccination)\n\n          -  Patient able to give his consent and having signed a written Informed consent\n\n          -  Patient affiliated to social security system, if applicable\n\n          -  Male patients must practice complete abstinence or agree to use a condom during\n             sexual contact  with a pregnant female or a female of childbearing potential while\n             participating in the study, during dose interruptions, and for 3 months following\n             study drug discontinuation, even if he has undergone a successful vasectomy.\n\n          -  All patients must agree to fulfill the global Lenalidomide Pregnancy Prevention Risk\n             Management Plan as applicable according to the randomization arm (randomization arm)\n\n        Exclusion Criteria:\n\n          -  Any other histological type of lymphoma, Burkitt included\n\n          -  Any history of treated or non-treated small-B cell lymphoma\n\n          -  Central nervous system or meningeal involvement by lymphoma\n\n          -  Contra-indication to any drug contained in the chemotherapy regimens ; for\n             anthracycline use, ejection fraction should be > 50%\n\n          -  Any serious active disease (according to the investigator's decision)\n\n          -  History of deep venous thrombosis or arterial thromboembolism events within the past\n             12 months before inclusion\n\n          -  Poor renal function (creatinine clearance < 40 ml/min, according to MDRD formula)\n\n          -  Poor hepatic function (total bilirubin level >30mmol/l, transaminases >2.5 maximum\n             normal level) unless these abnormalities are related to the lymphoma\n\n          -  Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l,\n             unless related to bone marrow infiltration\n\n          -  Any history of cancer during the last 5 years with the exception of non-melanoma skin\n             tumors or stage 0 (in situ) cervical carcinoma Patients previously diagnosed with\n             prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason\n             score \u22647, and a prostate specific antigen (PSA) \u226410 ng/mL prior to initial therapy,\n             (2) they had definitive curative therapy (i.e., prostatectomy or radiotherapy) 2\n             years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they\n             had no clinical evidence of prostate cancer, and their PSA was undetectable if they\n             underwent prostatectomy or <1 ng/mL if they did not undergo prostatectomy\n\n          -  Treatment with any investigational drug within 30 days before planned first cycle of\n             chemotherapy and during the study\n\n          -  Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months\n             prior to start of therapy\n\n          -  Prior use of lenalidomide\n\n          -  Prior \u2265 Grade 3 allergic reaction/hypersensitivity to thalidomide\n\n          -  Prior \u2265 Grade 3 rash or any desquamating (blistering) rash while taking thalidomide\n\n          -  Subjects with \u2265 Grade 2 neuropathy\n\n          -  Adult patient under tutelage\n\n          -  Female of childbearing potential are excluded. (Note: Females are defined as not of\n             childbearing potential if there is documentation of \"natural menopause for at least\n             24 consecutive months, a hysterectomy or bilateral oophorectomy\")"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "80 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128061", 
            "org_study_id": "SENIOR"
        }, 
        "intervention": [
            {
                "arm_group_label": "R2-miniCHOP", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Revlimid"
            }, 
            {
                "arm_group_label": [
                    "R-miniCHOP", 
                    "R2-miniCHOP"
                ], 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "Mabthera"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "f.bijou@bordeaux.unicancer.fr", 
                    "last_name": "Fontanet BIJOU, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "investigator": {
                    "last_name": "Fontanet BIJOU, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "laurent.voillat@ch-chalon71.fr", 
                    "last_name": "Laurent VOILLAT, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ch\u00e2lon sur S\u00e2one", 
                        "country": "France"
                    }, 
                    "name": "CHU de Ch\u00e2lon sur S\u00e2one"
                }, 
                "investigator": {
                    "last_name": "Laurent VOILLAT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ehermet@chu-clermontferrand.fr", 
                    "last_name": "Eric HERMET, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clermont-Ferrand", 
                        "country": "France", 
                        "zip": "63000"
                    }, 
                    "name": "CHU d'Estaing"
                }, 
                "investigator": {
                    "last_name": "Eric HERMET, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "corinne.haioun@hmn.aphp.fr", 
                    "last_name": "Corinne HAIOUN, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "APHP - Hopital Henri Mondor"
                }, 
                "investigator": {
                    "last_name": "Corinne HAIOUN, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "olivier.casasnovas@chu-dijon.fr", 
                    "last_name": "Olivier CASASNOVAS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21034"
                    }, 
                    "name": "CHU de Dijon - H\u00f4pital le Bocage"
                }, 
                "investigator": {
                    "last_name": "Olivier CASASNOVAS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rgressin@chu-grenoble.fr", 
                    "last_name": "R\u00e9my GRESSIN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "zip": "38000"
                    }, 
                    "name": "CHU de Grenoble"
                }, 
                "investigator": {
                    "last_name": "R\u00e9my GRESSIN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hfarhat@ch-versailles.fr", 
                    "last_name": "Hassan Farhat, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Le Chesnay", 
                        "country": "France", 
                        "zip": "78157"
                    }, 
                    "name": "CH de Versailles - Hopital Andr\u00e9 Mignot"
                }, 
                "investigator": {
                    "last_name": "Hassan FARHAT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.morschhauser@chru-lille.fr", 
                    "last_name": "Franck MORSCHHAUSER, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU Lille - H\u00f4pital Claude Huriez"
                }, 
                "investigator": {
                    "last_name": "Franck MORSCHHAUSER, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.ghesquieres@lyon.unicancer.fr", 
                    "last_name": "Herv\u00e9 GHESQUIERES, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "investigator": {
                    "last_name": "Herv\u00e9 GHESQUIERES, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "steven.legouill@chu-nantes.fr", 
                    "last_name": "Steven LEGOUILL, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU de Nantes"
                }, 
                "investigator": {
                    "last_name": "Steven LEGOUILL, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "frederic.peyrade@nice.unicancer.fr", 
                    "last_name": "Fr\u00e9d\u00e9ric PEYRADE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06189"
                    }, 
                    "name": "Centre Antoine Lacassagne"
                }, 
                "investigator": {
                    "last_name": "Fr\u00e9d\u00e9ric PEYRADE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.thieblemont@sls.aphp.fr", 
                    "last_name": "Catherine THIEBLEMONT, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75475"
                    }, 
                    "name": "APHP - H\u00f4pital Saint Louis"
                }, 
                "investigator": {
                    "last_name": "Catherine THIEBLEMONT, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "richard.delarue@nck.aphp.fr", 
                    "last_name": "Richard DELARUE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75743"
                    }, 
                    "name": "APHP - H\u00f4pital Necker"
                }, 
                "investigator": {
                    "last_name": "Richard DELARUE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "krimo.bouabdallah@chu-bordeaux.fr", 
                    "last_name": "Kamal BOUABDALLAH, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }, 
                    "name": "CHU du Haut Leveque"
                }, 
                "investigator": {
                    "last_name": "Kamal BOUABDALLAH, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gilles.salles@chu-lyon.fr", 
                    "last_name": "Gilles SALLES, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre-B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Chu Lyon Sud"
                }, 
                "investigator": {
                    "last_name": "Gilles Salles, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thierry.lamy.de.la.chapelle@chu-rennes.fr", 
                    "last_name": "Thierry LAMY, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU de Rennes"
                }, 
                "investigator": {
                    "last_name": "Thierry LAMY, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "herve.tilly@chb.unicancer.fr", 
                    "last_name": "Herv\u00e9 TILLY, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "investigator": {
                    "last_name": "Herv\u00e9 TILLY, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "c.fruchart@baclesse.unicancer.fr", 
                    "last_name": "Christophe FRUCHART, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "14076"
                    }, 
                    "name": "Centre Fran\u00e7ois Baclesse"
                }, 
                "investigator": {
                    "last_name": "Christophe FRUCHART, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sandra.malak@curie.net", 
                    "last_name": "Sandra MALAK, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint-Cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }, 
                    "name": "Centre Ren\u00e9 Huguenin - Institut Curie"
                }, 
                "investigator": {
                    "last_name": "Sandra MALAK, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gaudin.c@chu-toulouse.fr", 
                    "last_name": "Cl\u00e9ment GAUDIN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Purpan - Toulouse"
                }, 
                "investigator": {
                    "last_name": "Cl\u00e9ment GAUDIN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "helene.monjanel@univ-tours.fr", 
                    "last_name": "H\u00e9l\u00e8ne MONJANEL, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "CHRU Bretonneau"
                }, 
                "investigator": {
                    "last_name": "H\u00e9l\u00e8ne MONJANEL, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "s.bologna@chu-nancy.fr", 
                    "last_name": "Serge BOLOGNA, MD, Prof"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre les Nancy", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "CHU de Brabois"
                }, 
                "investigator": {
                    "last_name": "Serge BOLOGNA, MD, prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalinomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA.", 
        "overall_contact": {
            "email": "stephane.vincent@lysarc.org", 
            "last_name": "St\u00e9phane Vincent, PharmD", 
            "phone": "+33 (0) 4 27 01 27 35"
        }, 
        "overall_official": {
            "affiliation": "The Lymphoma Study Association - LYSA", 
            "last_name": "Fabrice Jardin, MD,Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "OS will be measured from the date of randomization to the date of death from any cause. Alive patients will be censored at their last contact.", 
            "measure": "The overall survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "OS rates at 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the time from randomization into the study to the first observation of documented disease progression/relapse or death due to any cause. If a subject has not progressed or died, PFS will be censored at the time of last visit with adequate assessment.", 
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "PFS rates at 2 years"
            }, 
            {
                "description": "EFS will be measured from the date of randomization to the date of first documented disease progression/relapse (Cheson 1999), initiation of new anti-lymphoma therapy or death from any cause. Patients without documented event at the time of analysis will be censored at their visit with adequate assessment.", 
                "measure": "Event-Free Survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "EFS rates at 2 years"
            }, 
            {
                "description": "DoR will be measured from the time of attainment of CR/CRu or PR to the date of first documented disease progression/relapse or death from any cause. Patients alive and free of progression will be censored at their last visit with adequate assessment.", 
                "measure": "Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "DoR rates at 2 years"
            }, 
            {
                "description": "DFS will be measured from the date of attainment of a complete or unconfirmed complete response (at the end of treatment or at permanent treatment discontinuation evaluation) to the date of first observation of documented disease progression or death due to any cause. CR/CRu patients who have not progressed or died will be censored at the time of last visit with adequate assessment.", 
                "measure": "Disease-Free Survival (DFS)", 
                "safety_issue": "No", 
                "time_frame": "DFS rates at 2 years"
            }, 
            {
                "description": "OS will be described for the R2-miniCHOP group according to Hans algorithm (GCB/non-GCB phenotype).", 
                "measure": "OS according to GCB/non-GCB phenotype", 
                "safety_issue": "No", 
                "time_frame": "OS according to GCB/non-GCB phenotype rates at 2 years"
            }, 
            {
                "description": "Disease response evaluation at end of treatment (after 6 cycles) will be used to determine the Response Rate. Response will be assessed at end of treatment (after end of the 6th cycle of treatment or at permanent treatment discontinuation).\nAssessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999)).", 
                "measure": "Response Rate at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "22 weeks (28 days after the end of the 6, three-weeks interval, cycles of treatment) or within 28 days following permanent treatment discontinuation"
            }, 
            {
                "description": "Four geriatric tools will be performed before any chemotherapy administration (IADL, MNA, G8, and CIRS-G scales). Each scale will be analyzed in order to have a picture of the population at baseline. Thereafter, the prognosis impact in OS and PFS of each scale will be evaluated using univariate (Kaplan Meier) and multivariate analyses (Cox model). Safety analyses will also be performed according to each scale in order to evaluate the toxicity predictive power of these scales.", 
                "measure": "Simplified Geriatric Scales", 
                "safety_issue": "Yes", 
                "time_frame": "At baseline"
            }, 
            {
                "description": "Health related Quality of Life will be assessed by the QLQ-C30 and the QLQ-ELD14 at randomization and at end of treatment. The improvement or not of the QoL will therefore be assessed.\nThe QLQ-ELD14 was developed to supplement the QLQ-C30 for measuring HRQoL in patients aged >70 years in oncology studies.", 
                "measure": "HRQOL", 
                "safety_issue": "No", 
                "time_frame": "At randomization and 22 weeks after Day 1 of Cycle 1 of R-miniCHOP or R2-miniCHOP (28 days after the end of the 6, three-weeks interval, cycles of treatment)"
            }
        ], 
        "source": "The Lymphoma Academic Research Organisation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Lymphoma Academic Research Organisation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}